Shares of Cannabis Science Inc (OTCMKTS: CBIS) are looking to bottom out, from one-year lows, after a rollercoaster first quarter. The stock has had to contend with wild swings since the start of the year.
After starting the year on a roll and rallying by more than 50%, the stock did succumb to bearish pressure consequently plunging to the $0.03 level.
CBIS Catalysts And Price Analysis
With the stock having taken out the $0.04 level, it might as well have hit the floor and due for a correction higher as a bounce-back play. Some of the catalysts triggering a rally from current lows is the confirmation that the company is expanding its footprint into Canada.
In the recent past, the company has also confirmed the formation iCannabinoid Ambassadors Program. The program is geared towards expanding the company’s footprint and supporting the development of initiatives into new markets.
Cannabis Science has also confirmed plans to expand the scope of its sponsored research in Nigeria to address the potential use of CBD to treat neurological conditions such as Post Traumatic Disorder.
A bounce back from the $0.03 level could as well signal revitalized investors sentiments in the wake of recent developments. After the recent bounce back, the $0.05 is the immediate resistance level standing in the way of the stock edging higher from current lows.
Cannabis Science needs to rally and find support above the $0.05 mark if it is to stay on track to correct higher after crashing in recent months. For the stock to turn bullish as a long-term play then it will have to rally and takeout the $0.06 resistance level.
What Does Cannabis Science Do?
Cannabis Science with its subsidiaries is engaged in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. The company is currently working on cannabis-infused products for addressing autism, blood pressure as well as cancer among other illnesses.
Shares of Cannabis Sciences have started bottoming out on the company announcing plans to expand into Canada in pursuit of opportunities for growth. The company has since confirmed the formation of Cannabis Science Canada, a wholly-owned subsidiary, tasked with pursuing opportunities in Canada.
With the new subsidiary in place, the company has already begun negotiations for Canadian land where it plans to launch cannabis cultivation and production operations. The company is also pursuing relevant licenses.
“We currently have a number of very important research and drug-development initiatives underway in the U.S., Europe, South America, and in Sub-Saharan Africa. As we expand into Canada, the Company can leverage these opportunities in order to rapidly grow our business model in Canada and begin releasing our exciting product lines,” stated CEO Raymond Dabney.
Dabney expects Canada to be an important market for Cannabis Science in the wake of recreational use legalization. In addition to selling cannabis products, the company is also planning to engage in cannabis research and drug development activities.
iCannabinoid Ambassador Program
Expansion into Canada is not the only thing working for Cannabis Science. The company has since confirmed the formation of iCannabinoid Ambassador Program whose members are tasked with the responsibility of expanding the company’s footprint into new markets.
Each ambassador under the new program will be designated an area of interest and expertise to help educate the public about the company’s initiatives. The core objective with the new program is to take advantage of the consortium of partnerships and licensing programs for patents as well as other product development initiatives.
Cannabis Sciences has already opened discussions as it seeks to license its U.S Patent for the composition of cannabinol for treatment of various Neurobehavioral Disorders including sleep disorder and PTSD.
“There are so many products we are developing for current market conditions for sleep deprivation, anxiety, PTSD, and many more neurological conditions. […]Our formulations, product testing, and manufacturing and packaging will be split between several facilities in the United States and Canada,” added Mr. Dabney.
Cannabis Science has had to contend wild price swings in recent months after starting the year on a roll and then coming under pressure. Recent price action activity indicates that the stock has hit bottom and due for a correction higher.
The company has already served a number of catalysts starting with the expansion into Canada as well as plans to develop new CBD therapies for addressing various medical conditions that continue to prop market sentiments.
For those looking for a bounce-back play with a good risk/reward setup, CBIS is worth a look.
For the latest updates on CBIS and other CBD stocks, sign up below!
Disclosure: We have no position in CBIS and have not been compensated for this article.
Can Isodiol International Inc (CNSX:ISOL)(OTCMKTS:ISOLF) Break Out From Here?
Investors have jumped on Isodiol International Inc (CNSX:ISOL)(OTCMKTS:ISOLF) stock this month. The stock gained 62% on January 21, marking its best day so far in 2020. The stock has already gained 106% year-to-date. But do not think even for a minute that investors have warmed up to Isodiol stock for nothing. This is a stock with tremendous potential and at this point, the stock is just showing early signs of what is going to be a big breakout.
In case you are wondering why investors have started jostling for a piece of Isodiol early on in the year, this report answers that question and more. But before we delve into the details, it is important to first understand the company we’re discussing here.
About Isodiol International
Isodiol International is a Canadian company that has specialized in the making of pharmaceutical and consumer products derived from hemp. It makes CBD products derived from hemp grown and processed in the United States. Though Isodiol’s operations are currently concentrated in North America, the company has big expansion dreams. It has set its sights on expanding into Latin America, Asia, and Europe.
What exactly is drawing investors to Isodiol stock and why does it stand out as a good pick in the hemp/cannabis stock universe in 2020? The simple answer is that investors are beginning to realize Isodiol’s bright prospects as a CBD products company.
Isodiol bidding for…
New Age Beverage (NASDAQ:NBEV) Solid Fundamentals Amidst Price Slump
New Age Beverage (NASDAQ:NBEV) has taken a significant beating since the start of the year. A 60% plus slide attests to a stock under immense pressure. Amidst the underperformance in the stock market, the company has continued to do exceedingly well when it comes to core business execution and operation efficiency.
New Age Beverage Catalysts And Price Analysis
Triple-digit revenue growth is one of the developments that continues to affirm the company’s long-term prospects. The company also remains well-positioned to generate bottom-line growth backed by robust retail channels in the U.S as well as expansion in Asia. Integration of Morinda operations in China is another development likely to continue strengthening the company’s bottom line going forward.
A spike in implied volatility in the options market is the latest development that signals a potential turnaround in the direction of trade. Huge implied volatility indicates that trade is developing. What is clear is that the stock has taken a significant hit and may be due for a correction higher, given the improving fundamentals.
Increased activity around the $2.50 Put options could signal a potential change in the direction of trade. After the recent slide lower, the stock needs to rise and find support above the $2.40 resistance level. A rally past the $2.40 level should reaffirm New Age Beverages bounce back prospects.
Above the crucial resistance level, the stock should be on its way to the…
Charlotte’s Web Stock (TSE:CWEB) (OTCMKTS:CWBHF) Poised For Breakout And Here’s Why
Charlotte’s Web Stock (TSE:CWEB) (OTCMKTS:CWBHF) is currently at one of its lowest price levels in about five months. That is the result of a selloff that kicked off toward late September after the stock reached one of its highest watermarks at $23 in August.
You cannot rule out profit-taking as having contributed to the decline that has brought the stock to its current lows considering the stock pulled up from one of its lowest levels this year in July before the August breakout. A repeat of the August bull run that powered CWBHF to one of its highest price levels this year seems to be in the offing.
Firstly, after a string of declines for much of last week and early this week, CWBHF has begun showing signs of a comeback. The stock closed the last session (November 5), up. Now the stock has found immediate support at $10.9 from where it looks set for a powerful breakout as happened in March, June, and July.
In March, for instance, CWBHF bolted from a low of $13 on March 8 to reach its one-year peak of $25 in a space of fewer than 30 days on April 4. Profit-taking kicked off after that and the stock fell to around $10 in mid-June, from where it began rising again, topping $18.5 in early July. Investors again took profit and toward late July the stock was back down at around $13.5.…